GSK's Tykerb gains FDA approval for use in combo therapy

01/31/2010 | Reuters

The FDA approved the use of GlaxoSmithKline's breast cancer drug Tykerb in combination with Novartis' Femara to treat hormone- and HER2-positive advanced breast cancer in postmenopausal patients under hormonal therapy. A study showed that cancer progression was suppressed for 35 weeks in women using Tykerb and Femara together, compared with 13 weeks for those who received Femara alone.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC